Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study

DOI: 10.1093/ndt/gfq336
Nephrology Dialysis Transplantation, 2010, 25, 2846-50.

#	Paper	IF	Citations
132	Management of anemia and iron deficiency in heart failure. **2010**, 12, 532-48		5
131	Come cambiata la gestione dell'anemia per i pazienti in dialisi alla luce dello studio DOPPS. **2010**, 22, 27-33		1
130	Bundled-rate legislation for Medicare reimbursement for dialysis services: implications for anemia management with ESAs. **2010**, 5, 2355-62		14
129	Individualizing anaemia therapy. *CKJ: Clinical Kidney Journal*, **2010**, 3, 519-26	4.5	
128	[TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4]. *Nephrologie Et Therapeutique*, **2011**, 7, 2-9	0.6	6
127	[Feasibility strategy of darbepoetin alfa administration every other week: 2005-2007 experience in a dialysis unit]. *Nephrologie Et Therapeutique*, **2011**, 7, 549-57	0.6	1
126	Should erythropoiesis-stimulating agents be used in predialysis patients?. **2011**, 64, 149-50		
125	Erythropoietic therapy: time for some changes. **2011**, 3, 6-9		
124	Bibliography. Pharmacology and therapeutics. Current world literature. **2011**, 20, 561-7		
123	Current world literature. **2011**, 26, 356-61		
122	Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient. **2011**, 20, 465-70		5
121	Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in hemodialysis patients. **2011**, 11, 181-7		3
120	Extraordinary popular delusions and the madness of crowds: puncturing the epoetin bubble--lessons for the future. *Nephrology Dialysis Transplantation*, **2011**, 26, 24-8	4.3	6
119	Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach?. *Nephrology Dialysis Transplantation*, **2011**, 26, 2069-71	4.3	8
118	[Chronic renal failure]. **2011**, 136, 1591-3		2
117	Kardiorenales Anämiesyndrom – Die nephrologische Sichtweise. **2011**, 15, 392-404		
116	Erythropoiesis-stimulating agents in renal medicine. **2011**, 16 Suppl 3, 19-24		22

115	Impact of hemodialysis therapy on anemia of chronic kidney disease: the potential mechanisms. **2011**, 32, 210-9		22
114	Anemia trials in CKD and clinical practice: refining the approach to erythropoiesis-stimulating agents. **2011**, 171, 248-254		3
113	Do two intravenous iron sucrose preparations have the same efficacy?. *Nephrology Dialysis Transplantation*, **2011**, 26, 3262-7	4.3	61
112	Erythropoietin in kidney disease and type 2 diabetes. **2011**, 364, 385; author reply 385-6		4
111	Iron treatment and the TREAT trial. *CKJ: Clinical Kidney Journal*, **2011**, 4, i3-i5	4.5	3
110	Reimbursement of dialysis: a comparison of seven countries. *Journal of the American Society of Nephrology: JASN*, **2012**, 23, 1291-8	12.7	94
109	The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS study. **2012**, 7, 52-9		16
108	Anemia management in patients on peritoneal dialysis. **2012**, 178, 89-94		3
107	A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). **2012**, 38, 783-96		30
106	An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. *Nephrology Dialysis Transplantation*, **2012**, 27, 2303-11	4.3	8
105	Correction of postkidney transplant anemia reduces progression of allograft nephropathy. *Journal of the American Society of Nephrology: JASN*, **2012**, 23, 360-8	12.7	80
104	Renal anemia treatment with ESA in hemodialysis patients in relation to early versus late referral in everyday clinical practice in Central and Eastern European countries: baseline data. **2012**, 35, 58-67		2
103	The Story of Erythropoietin. **2012**, 687-695		2
102	Prevalence and predictors of the sub-target Hb level in children on dialysis. *Nephrology Dialysis Transplantation*, **2012**, 27, 3950-7	4.3	16
101	Recommendation for the management of crush victims in mass disasters. *Nephrology Dialysis Transplantation*, **2012**, 27 Suppl 1, i1-67	4.3	69
100	Reply. *Nephrology Dialysis Transplantation*, **2012**, 27, 454-455	4.3	
99	Prospective randomized pilot study on the effects of two synthetic high-flux dialyzers on dialysis patient anemia. **2012**, 35, 346-51		2
98	An expert opinion on the current treatment of anemia in patients with kidney disease. **2012**, 13, 495-503		15

97	Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?. **2012**, 16, 819-26		38
96	A role for the membrane proteome in human chronic kidney disease erythrocytes. **2012**, 160, 374-83		14
95	The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers. **2012**, 23, 352-8		14
94	Chronic kidney disease and diabetes. **2012**, 71, 94-103		58
93	[Prepare: cross-sectional study on management of chronic kidney disease by nephrologists before dialysis in France]. *Nephrologie Et Therapeutique*, **2012**, 8, 439-50	0.6	1
92	Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study. *BMC Nephrology*, **2012**, 13, 60	2.7	7
91	Cardiovascular Disease in Diabetic Nephropathy: Pathophysiology and Treatment. **2012**, 83-100		
90	Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study. **2012**, 32, 99-110		9
89	Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease. **2012**, 11, 923-31		9
88	Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients. **2012**, 16, 11-9		10
87	Iron therapy in patients with chronic kidney disease. **2012**, 12, 115-121		3
86	Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. *American Journal of Nephrology*, **2013**, 37, 549-58	4.6	88
85	Pocket Reference to Renal Anemia. **2013**,		1
84	Challenges in the management of the blood supply. **2013**, 381, 1866-75		153
83	Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. *Nephrology Dialysis Transplantation*, **2013**, 28, 3035-45	4.3	48
82	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. *Nephrology Dialysis Transplantation*, **2013**, 28, 1346-59	4.3	479
81	Diagnostic, suivi biologique de l□insuffisance r□ale chronique et prise en charge de l□insuffisance r□ale chronique terminale. **2013**, 2013, 59-73		3
80	Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational study. *BMC Nephrology*, **2013**, 14, 243	2.7	1

79	Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. **2013**, 3,	16
78	Clinical Characteristics and Course of Patients Entering Cardiac Rehabilitation with Chronic Kidney Disease: Data from the Italian Survey on Cardiac Rehabilitation. **2013**, 2013, 1-10	1
77	Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients. **2013**, 35, 314-9	7
76	rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients Risks and Benefits. **2013**,	
75	Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. **2013**, 8, 3297-307	7
74	Management of Anemia on Hemodialysis. **2013**,	1
73	What's the Latest on Iron Therapy?. **2014**, 26, 296-300	1
72	Heart failure in patients with chronic kidney disease: a systematic integrative review. **2014**, 2014, 937398	85
71	Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. **2014**, 3, 156-68	53
70	Renal Disease in the Tropics. **2014**, 933-951.e5	
69	Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies. **2014**, 7, 495-506	24
68	The Prevention and Treatment of Coronary Artery Disease in Kidney Transplant Recipients. **2014**, 189-198	
67	Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up. **2014**, 46, 71-82	0
66	Kidney Transplantation. **2014**,	2
65	Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011. **2014**, 57, 718-28	36
64	Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome. **2014**, 46, 453-9	7
63	Effect of erythropoiesis-stimulating agents on hemoglobin level, fatigue and hospitalization rate in renal palliative care patients. **2014**, 46, 653-7	8
62	New treatment approaches in chronic kidney disease-associated anaemia. **2014**, 14, 687-96	9

61	Intestinal adsorption of uraemic toxins: a new strategy for anaemia management?. *Nephrology Dialysis Transplantation*, **2014**, 29, 1620-4	4.3	3
60	Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. **2014**,		1
59	[Anemia: From Basic Knowledge to Up-to-Date Treatment. Topic: VII. Anemia in chronic kidney disease]. **2015**, 104, 1414-24		
58	Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. **2014**, 128, 323-32		10
57	Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. *The Cochrane Library*, **2015**, CD011122	5.2	6
56	8.5 Ratschl□e zur Abkl□ung und Betreuung von Patienten mit chronischer Nierenerkrankung. **2015**,		
55	Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study. **2015**, 35, 179-188		3
54	Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. *Nephrology Dialysis Transplantation*, **2015**, 30, 1979-88	4.3	25
53	Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study. **2015**, 35, 179-88		3
52	Acute ischemic stroke and abnormal blood hemoglobin concentration. **2016**, 134, 123-30		23
51	[Erythropoietin, chronic renal failure and cancer]. **2016**, 146, 539-40		0
50	An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. **2016**, 15, 1021-30		253
49	Erythropoietin, chronic renal failure and cancer. **2016**, 146, 539-540		
48	Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. *Nephrology Dialysis Transplantation*, **2016**, 31, 2073-2085	4.3	1
47	Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region. **2016**, 29, 673-81		5
46	Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. *Nephrology Dialysis Transplantation*, **2016**, 31, 628-35	4.3	22
45	International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 2205-15	12.7	25
44	Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD). **2016**, 4, e12732		18

43	The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. **2016**, 36, 421-31		7
42	Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. *Journal of the American Society of Nephrology: JASN*, **2016**, 27, 1234-44	12.7	124
41	Iron therapy in chronic kidney disease: Recent changes, benefits and risks. **2016**, 30, 65-72		23
40	Short Stay Management of Acute Heart Failure. *Contemporary Cardiology*, **2017**,	0.1	
39	Current and future chemical therapies for treating anaemia in chronic kidney disease. **2017**, 18, 781-788		7
38	New Strategies for Anaemia Management in Chronic Kidney Disease. **2017**, 189, 184-188		6
37	A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of chronic kidney disease. **2017**, 8, 305-318		2
36	Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. *BMC Nephrology* , **2017**, 18, 345	2.7	117
35	Improving Erythropoiesis Stimulating Agent Hyporesponsiveness in Hemodialysis Patients: The Role of Hepcidin and Hemodiafiltration Online. **2018**, 45, 139-146		12
34	The impact of chronic kidney disease on medication choice and pharmacologic management in patients with heart failure. **2018**, 11, 571-579		3
33	Usefulness of mid-week hemoglobin measurement for anemia management in patients undergoing hemodialysis: a retrospective cohort study. *BMC Nephrology*, **2019**, 20, 295	2.7	1
32	Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)?. *Clinical Nephrology*, **2019**, 91, 246-253	2.1	5
31	Parenteral versus oral iron therapy for adults and children with chronic kidney disease. *The Cochrane Library*, **2019**, 2, CD007857	5.2	13
30	Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. *Frontiers in Pharmacology*, **2018**, 9, 1498	5.6	10
29	Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study. *American Journal of Nephrology*, **2019**, 49, 470-478	4.6	29
28	Clinical practice guidelines for the provision of renal service in Hong Kong: Haemodialysis. *Nephrology*, **2019**, 24 Suppl 1, 41-59	2.2	1
27	Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study. *BMC Nephrology*, **2019**, 20, 81	2.7	1
26	"Doctor, can I have less frequent injection with highly efficient treatment?" A patient centered study using an electronic choice-based conjoint analysis (ePRO) to assess real world preferences regarding erythropoiesis stimulating agent to treat anaemia in chronic kidney disease (PERCEPOLIS study). *Nephrologie Et Therapeutique*, **2019**, 15, 152-161	0.6	1

25	T Cells Play a Causal Role in Diastolic Dysfunction during Uremic Cardiomyopathy. *Journal of the American Society of Nephrology: JASN*, **2019**,	12.7	11
24	Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. *Journal of Clinical Pharmacology*, **2019**, 59, 418-426	2.9	1
23	A pharmacist-managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial. *Pharmacology Research and Perspectives*, **2020**, 8, e00628	3.1	
22	Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study. *CKJ: Clinical Kidney Journal*, **2021**, 14, 1780-1788	4.5	2
21	Treatment practices and outcomes in incident peritoneal dialysis patients: the Swedish Renal Registry 2006-2015.. *CKJ: Clinical Kidney Journal*, **2021**, 14, 2539-2547	4.5	
20	Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. *BMC Nephrology*, **2021**, 22, 284	2.7	
19	Anemia: A Connection Between Heart Failure and Kidney Failure. *Cardiology Clinics*, **2021**, 39, 319-333	2.5	0
18	Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus. *Journal of Clinical Pharmacology*, **2021**,	2.9	
17	Soluble transferrin receptor as a marker of erythropoiesis in patients undergoing high-flux hemodialysis. *Bosnian Journal of Basic Medical Sciences*, **2017**, 17, 333-338	3.3	5
16	The differential effects of anemia on mortality in young and elderly end-stage renal disease patients. *Kidney Research and Clinical Practice*, **2020**, 39, 192-201	3.6	2
15	Gender Differences in Dose of Erythropoietin to Maintain Hemoglobin Target in Hemodialysis Patients. *Indian Journal of Nephrology*, **2019**, 29, 160-165	0.8	1
14	Guidelines on the Management of Renal Anemia. **2013**, 49-52		
13	Anaemia Management in Chronic Kidney Disease. **2014**, 569-579		1
12	Chronic Renal Transplant Dysfunction. **2016**, 1833-1873		
11	Heart Failure and Kidney Disease: Management in the Short-Stay Unit. *Contemporary Cardiology*, **2017**, 295-307	0.1	
10	Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience. *Croatian Medical Journal*, **2019**, 60, 475-478	1.6	1
9	Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience. *Medicinski Arhiv = Medical Archives = Archives De Médecine*, **2020**, 74, 109-114	1.2	1
8	Anemia management trends in patients on peritoneal dialysis in the past 10 years. *International Journal of Clinical and Experimental Medicine*, **2015**, 8, 18050-7		5

7	Randomised open-label trial comparing intravenous iron and an erythropoiesis-stimulating agent versus oral iron to treat preoperative anaemia in cardiac surgery (INITIATE trial).. *British Journal of Anaesthesia*, **2022**,	5.4	0
6	Clinical practice for outpatients that are chronically red cell dependent: A survey in the Netherlands.. *Vox Sanguinis*, **2021**,	3.1	
5	Peritoneal Dialysis Care in Chinese mainland: A Nationwide Survey (Preprint).		
4	Resistance to Erythropoiesis Stimulating Agent (ESA) Treatment. **2023**, 351-362		
3	Peritoneal Dialysis Care in Mainland China: A Nationwide Survey (Preprint).		0
2	Anemia biomarkers and mortality in hemodialysis patients with or without diabetes: A 10-year follow-up study. **2023**, 18, e0280871		0
1	The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. **2023**,		0